Antimalarial pharmacodynamics and pharmacokinetics of a third-generation antifolate - JPC2056 - In cynomolgus monkeys using an in vivo - in vitro model

Journal of Antimicrobial Chemotherapy

Volumn 60, Issue 4, 2007, Pages 811-818

  Edstein, Michael D ^a   Kotecka, Barbara M ^a   Ager, Arba I ^b   Smith, Kirsten S ^c   Ditusa, Charles A ^c   Diaz, Damaris S ^c   Kyle, Dennis E ^c   Schiehser, Guy A ^d   Jacobus, David P ^d   Rieckmann, Karl H ^a   O'Neil, Michael T ^a,c  

^a AUSTRALIAN ARMY MALARIA INSTITUTE   (Australia)

^b UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^c WALTER REED ARMY INSTITUTE OF RESEARCH   (United States)

^d Jacobus Pharmaceutical Co Inc   (United States)

Author keywords

Antifolates; DHFR inhibitors; JPC2056; Malaria; WR99210

Indexed keywords

4,6 DIAMINO 1,2 DIHYDRO 2,2 DIMETHYL 1 [3 (2,4,5 TRICHLOROPHENOXY)PROPOXY] 1,3,5 TRIAZINE; ANTIMALARIAL AGENT; CHLORCYCLOGUANIL; DIHYDROFOLATE REDUCTASE; DIHYDROFOLATE REDUCTASE INHIBITOR; DRUG METABOLITE; FOLIC ACID ANTAGONIST; JPC 2056; JPC 2067; PYRIMETHAMINE; THYMIDYLATE SYNTHASE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIMALARIAL ACTIVITY; AREA UNDER THE CURVE; ARTICLE; BLOOD SAMPLING; CONCENTRATION RESPONSE; CONTROLLED STUDY; DOSAGE SCHEDULE COMPARISON; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG ELIMINATION; DRUG HALF LIFE; DRUG POTENCY; DRUG STRUCTURE; DRUG TRANSFORMATION; IN VITRO STUDY; IN VIVO STUDY; LIQUID CHROMATOGRAPHY; MALARIA; MALE; MASS SPECTROMETRY; MONKEY; MUTANT; NONHUMAN; PLASMODIUM FALCIPARUM; PLASMODIUM VIVAX; REPEATED DRUG DOSE; SINGLE DRUG DOSE; WILD TYPE;

ANIMALS; ANTIMALARIALS; ATTENTION; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DRUG RESISTANCE, MICROBIAL; HALF-LIFE; MACACA FASCICULARIS; MALE; MASS SPECTROMETRY; PARASITIC SENSITIVITY TESTS; PLASMA; PLASMODIUM FALCIPARUM; PLASMODIUM VIVAX;

EID: 34548731273     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkm280     Document Type: Article

References (49)

1. Cowman AF, Morry MJ, Biggs BA et al. Amino acid changes linked to pyrimethamine resistance in the dihydrofolate reductase-thymidylate synthase gene of Plasmodium falciparum. Proc Natl Acad Sci USA 1988; 85; 9109-13.
2. Peterson DS, Walliker D, Wellems TE. Evidence that a point mutation in dihydrofolate reductase-thymidylate synthase confers resistance to pyrimethamine in falciparum malaria. Proc Natl Acad Sci USA 1988; 85: 9114-8.
3. de Pecoulas PE, Tahar R, Ouatas T et al. Sequence variations in the Plasmodium vivax dihydrofolate reductase-thymidylate synthase gene and their relationship with pyrimethamine resistance. Mol Biochem Parasitol 1998; 92: 265-73.
4. Leartsakulpanich U, Imwong M, Pukrittayakamee S et al. Molecular characterization of dihydrofolate reductase in relation to antifolate resistance in Plasmodium vivax. Mol Biochem Parasitol 2002; 119 63-73.
5. Kongsaeree P, Khongsuk P, Leartsakulpanich U et al. Crystal structure of dihydrofolate reductase from Plasmodium vivax: pyrimethamine displacement linked with mutation-induced resistance. Proc Natl Acad Sci USA 2005; 102: 13046-51.
6. Yuthavong Y, Yuvaniyama J, Chitnumsub P et al. Malarial (Plasmodium falciparum) dihydrofolate reductase-thymidylate synthase: structural basis for antifolate resistance and development of effective inhibitors. Parasitology 2005; 130: 249-59.
7. Yuvaniyama J, Chitnumsub P, Kamchonwongpaisan S et al. Insights into antifolate resistance from malarial DHFR-TS structures. Nat Struct Biol 2003; 10: 357-65.
8. Rieckmann KH. The in vitro activity of experimental antimalarial compounds against strains of Plasmodium falciparum with varying degrees of sensitivity to pyrimethamine and chloroquine. In: Chemotherapy of Malaria and Resistance to Antimalarials. Geneva: World Health Organization, 1973; World Health Organization Technical Report Series No. 529; 58.
9. Canfield CJ. New antimalarials under development. In: Bruce-Chwatt LJ. ed Chemotherapy of Malaria. Geneva: World Health Organization, 1986; World Health Organization Monograph Series No. 27; 99-100.
10. Canfield CJ, Milhous WK, Ager AL et al. PS-15: A potent, orally active antimalarial from a new class of folic acid antagonists. Am J Trop Med Hyg 1993; 49: 121-6.
11. Childs GE, Lambros C. Analogues of N-benzyloxydihydrotriazine: in vitro antimalarial activity against Plasmodium falciparum. Ann Trop Med Parasitol 1986; 80: 177-81.
12. Edstein MD, Bahr S, Kotecka B et al. In vitro activities of the biguanide PS-15 and its metabolite, WR99210, against cycloguanil-resistant Plasmodium falciparum isolates from Thailand. Antimicrob Agents Chemother 1997; 41: 2300-1.
13. Rieckmann KH, Yeo AET, Edstein MD. Activity of PS-15 and its metabolite, WR99210, against Plasmodium falciparum in an in vivo- in vitro model. Trans R Soc Trop Med Hyg 1996; 90: 568-71.
14. Jensen NP, Ager AL, Bliss RA et al. Phenoxypropoxybiguanides, prodrugs of DHFR-inhibiting diaminotriazine antimalarials. J Med Chem 2001; 44: 3925-31.
15. Shearer TW, Kozar MP, O'Neil MT et al. In vitro metabolism of phenoxypropoxybiguanide analogues in human liver microsomes to potent antimalarial dihydrotriazines. J Med Chem 2005; 48: 2805-13.
16. Schiehser GA, Shieh H-M, Nevchas IK et al. Selection of the third generation antifolate, JPC2056, as a pre-clinical development candidate. Am J Trop Med Hyg 2004; 71 Suppl 4:215.
17. Imwong M, Pukrittayakamee S, Looareesuwan S et al. Association of genetic mutations in Plasmodium vivax dhfr with resistance to sulfadoxine - pyrimethamine: Geographical and clinical correlates. Antimicrob Agents Chemother 2001; 45: 3122-7.
18. Imwong M, Pukrittayakamee S, Renia L et al. Novel point mutations in the dihydrofolate reductase gene of Plasmodium vivax: evidence for sequential selection by drug pressure. Antimicrob Agents Chemother 2003; 47: 1514-21.
19. Hastings MD, Maguire JD, Bangs MJ et al. Novel Plasmodium vivax dhfr alleles from the Indonesian Archipelago and Papua Now Guinea: association with pyrimethamine resistance determined by a Saccharomyces cerevisiae expression, system. Antimicrob Agents Chemother 2005; 49: 733-40.
20. Young, MD, Burgess RW., Pyrimethamine resistance in Plasmodium vivax malaria. Bull WHO 1959; 20 27-36.
21. Doberstyn EB, Teerakiartkamjom C, Andre RG et al. Treatment of vivax malaria with sulfadoxine-pyrimethamine and with pyrimethamine alone. Trans R Soc Trop Med Hyg, 1979; 73: 15-7.
22. Pukrittayakamee S, Chantra A, Simpson JA et al. Therapeutic responses to different antimalarial drugs in vivax malaria. Antimicrob Agents Chemother 2000; 44: 1680-5.
23. Tahar R, de Pecoulas PE, Basco LK et al. Kinetic properties of dihydrofolate reductase from wild-type and mutant Plasmodium vivax expressed in Escherichia coli. Mol Biochem Parasitol 2001; 113 241-9.
24. Hunt SY, Datering C, Varani G et al. Identification of the optimal third generation antifolate against P. falciparum and P. vivax. Mol Biochem Parasitol 2005; 144: 198-205.
25. Mehlotra RK, Lorry K, Kastens W et al. Random distribution of mixed species malaria infections in Papua New Guinea. Am J Trop Med Hyg 2000; 62: 225-31.
26. Mayxay MS, Pukrittayakamee S, Newton PN et al. Mixed-species malaria infections in humans. Trends Parasitol 2004; 20: 233-40.
27. Thaithong S, Beale GH. Resistance of ten Thai isolates of Plasmodium falciparum to chloroquine and pyrimethamine by in vitro tests. Trans R Soc Trop Med Hyg 1981; 75: 271-3.
28. Looareesuwan S, Viravan C, Webter HK et al. Clinical studies of atovaquone, alone or in combination with other antimalarial drugs, for treatment of acute uncomplicated malaria in Thailand. Am J Trop Med Hyg 1996; 54: 62-6.
29. Oduola AMJ, Weatherly NF, Bowdie JH et al. Plasmodium falciparum: cloning by single-erythrocyte micromanipulation and heterogeneity in vitro. Exp Parasitol 1988; 66: 86-95.
30. Auliff A, Wilson DW, Russell B et al. Amino acid mutations in Plasmodium vivax DHFR and DHPS from several geographical regions and susceptibility to antifolate drugs. Am J Trop Med Hyg 2006; 75 617-21.
31. O'Neil MT, Korsinczky MLJ, Gresty KJ et al. A novel Plasmodium falciparum expression system for assessing antifolate resistance caused by mutant P. vivax dihydrofolate reductase-thymidylate synthase. J Infect Dis 2007; 196: 467-74.
32. Rieckmann KH, Davis DR, Hutton DC. Plasmodium vivax resistance to chloroquine? Lancet 1989; 11: 1183-4.
33. Kotecka BM, Rieckmann KH. In vivo - in vitro model to assess chloroquine activity in monkeys. Chemotherapy 1995; 41: 134-40.
34. Talisuna AO, Nalunkuma-Kazibwe A, Langi P et al. Two mutations in dihydrofolate reductase combined with one in the dihydropteroate synthase gene predict sulphadoxine-pyrimethamine parasitological failure in Ugandan children with uncomplicated falciparum malaria. Infect Genet Evol 2004; 4: 321-7.
35. Gregson A, Plowe CV. Mechanisms of resistance of malaria parasites to antifolates. Pharmacol Rev 2005; 57: 117-45.
36. Watkins WM, Mberu EK, Winstanley PA et al. The efficacy of antifolate antimalarial combinations in Africa: A predictive model based on pharmacodynamic and pharmacokinetic analyses. Parasitol Today 1997; 13: 459-64.
37. Nzila AM, Nduati E, Mberu EK et al. Molecular evidence of greater selective pressure of drug resistance exerted by the long-acting antifolate pyrimethamine/sulfadoxine compared with the shorter-acting chlorproguanil/dapsone on Kenyan Plasmodium falciparum. J Infect Dis 2000, 181: 2023-8.
38. Kublin JG, Dzinjalamala FK, Kamwendo DD et al. Molecular markers for failure of sulfadoxine-pyrimethamine and chlorproguanil-dapsone treatment of Plasmodium falciparum malaria. J Infect Dis 2002; 185: 380-8.
39. White NJ. Antimalarial drug resistance: The pace quickens. J Antimicrob Chemother 1992; 30: 571-85.
40. Famert A, Tengstam K, Palme IB et al. Polyclonal Plasmodium falciparum malaria in travelers and selection of antifolate mutations after proguanil prophylaxis. Am J Trop Med Hyg 2002; 66: 487-91.
41. Bates SJ, Winstanley PA, Watkins WM et al. Rare, highly pyrimethamine-resistant alleles of the Plasmodium falciparum dihydrofolate reductase gene from 5 African sites. J Infect Dis 2004; 190: 1783-92.
42. Alker AP, Mwapasa V, Purfield A et al. Mutations associated with sulfadoxine - pyrimethamine and chlorproguanil resistance in Plasmodium falciparum isolates from Blantyre, Malawi. Antimicrob Agents Chemother 2005; 49: 3919-21.
43. McCollum AM, Poe AC, Hamel M et al. Antifolate resistance in Plasmodium falciparum: Multiple origins and identification of novel dhfr alleles. J Infect Dis 2006; 194: 189-97.
44. Wilairstana P, Kyle DE, Looareesuwan S et al. Poor efficacy of antimalarial biguanide - dapsone combinations in the treatment of acute, uncomplicated falciparum malaria in Thailand. Ann Trop Med Parasitol 1997; 91: 125-32.
45. Ferlan JT, Mookherjee S, Okezie IN et al. Mutagenesis of dihydrofolate reductase from Plasmodium, falciparum: Analysis in Saccharomyces cerevisiae of triple mutant alleles resistant to pyrimethamine or WR99210. Mol Biochem Parassitol 2001; 113: 139-50.
46. Hankins EG, Warhurst DC, Sibley CH. Novel alleles of the P. falciparum dhfr highly resistant to pyrimethamine and chlorcycloguanil, but not WR99210. Mol Biochem Parasitol 2001; 117: 91-102.
47. Edstein MD, Corcoran KD, Shanks GD et al. Evaluation of WR250417 (a proguanil analogue) for causal prophylactic activity in the Plasmodium cynomolgi - Macaca mulatta model. Am J Trop Med Hyg 1994; 50:1 81-6.
48. Mendis K, Sina BJ, Marchesini P et al. The neglected burden of Plasmodium vivax malaria. Am J Trop Med Hyg 2001; 64: 97-106.
49. Hastings MD, Porter KM, Maguire JD et al. Dihydrofolate reductase mutations in Plasmodium vivax from Indonesia and therapeutic response to sulfadoxine and pyrimethamine. J Infect Dis 2004; 189: 744-50.